GLENMARK PHARMACEUTICALS
|
The Current P/E Ratio of GLENMARK PHARMACEUTICALS is 52.34.
| Share Price | ₹1,975.2 | Feb 09,2026 |
| Market Cap | ₹55,740.1 Cr | |
| Earnings-TTM | ₹1,065.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 52.34x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹55,740.1 Cr] as on Feb 09,2026
(/) Earnings [ ₹1,065.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 52.34x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay 52.34 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS
PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 22.48x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 13.51x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 44.14x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 1,065.02 | 52.34 | 55,740.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.18 | 408,991.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 65.34 | 162,371.0 |
| CIPLA LTD | 4,544.70 | 23.86 | 108,441.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 63.19 | 135,229.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.32 | 106,407.0 |
| MANKIND PHARMA LTD | 1,796.65 | 47.85 | 85,977.0 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.83 | 92,885.5 |
| LUPIN LTD | 4,347.53 | 23.11 | 100,485.0 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.24 | 69,768.8 |
| ABBOTT INDIA LTD | 1,508.95 | 38.70 | 58,389.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.83x |
| Max industry PE | 65.34x |
| Median industry PE | 37.18x |
| Average industry PE | 37.27x |
You may also like the below Video Courses